-New features include compatibility with SureSigns VS4 spot
check monitors and connectivity with the Wearable Biosensor
-The IntelliVue Guardian Solution directing caregiver
attention to early signs of potential deteriorations can help
reduce costly resuscitation efforts or possible transfers to the
ICU
AMSTERDAM, Oct. 4, 2016 /PRNewswire/ -- Royal
Philips (NYSE: PHG AEX: PHIA) today announced the latest version of
the IntelliVue Guardian software, designed to aid clinicians in the
early recognition of subtle signs of patient deterioration in the
general care ward. This software can notify caregivers to early
signs of potential degradation, which can help reduce costly
complications, unplanned transfers back to the intensive care unit
and longer lengths of stay in the hospital.
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
This new iteration of the IntelliVue Guardian software (510(k)
pending – not for sale in USA) is configurable to most
institutions' Early Warning Scoring protocols, and includes new
features, such as compatibility with the SureSigns VS4 spot check
monitors, and the IntelliVue MP5SC monitor. The IntelliVue Guardian
software provides caregivers in general care wards with direct
access to an automated scoring system that can be based on
individual hospital policy.
The IGS Software is designed to help improve patient care,
financial outcomes and clinician workflow by facilitating early
intervention with Early Warning Score calculations. Having
automated tools that provide a comprehensive view into a patient's
condition helps enhance workflow efficiencies, simplify the medical
documentation process and better utilize limited staff
resources.
The new IntelliVue Guardian software can also be used with the
Philips Wearable Biosensor, (510(k) pending – not for sale in USA),
a medical-grade, self-adhesive, single patient-use wireless device
worn discreetly on the chest. The biosensor automatically and
continuously measures heart rate, respiratory rate, posture, and
detects falls, and this data will can be transmitted to the
IntelliVue Guardian software, which analyzes the combined trends of
the measurements over a configurable period of time and notifies
the appropriate caregiver or clinician when preset limits are
exceeded. It provides caregivers with peace of mind that their
patients are being monitored frequently for signs of deterioration
between spot checks while they are attending to other tasks. The
wireless Biosensor provides patients with freedom of mobility.
"Studies have shown that signs of clinical instability typically
occur six to eight hours prior to a potential deterioration and
that the most common predictors of this deterioration are changes
in respiratory and heart ratei," said Dr. Carla Kriwet, CEO Patient Care & Monitoring
Solutions. "The IntelliVue Guardian software—in tandem with the
Wearable Biosensor—allows for the continuous and automatic
collection and transmission of information to help caregivers
recognize these signs of instability earlier, before a
deterioration can occur."
The latest release of IGS software supporting the Wearable
Biosensor will be available from 05 October
2016 to countries requiring the CE Mark. This release is
pending FDA 510(k) clearance and is not for sale in the U.S. It
will expand on Philips' continuing commitment and leadership in
patient monitoring across the care continuum. The IntelliVue
Guardian software will be demonstrated at Philips booth #408 at the
29th European Society of Intensive Care Medicine (ESICM)
Annual Congress in Milan from
October 1-5, 2016.
For further information, please contact:
Kathy O'Reilly
Philips Group Communications
Tel: +1 978-659-2638
Mobile: +1 978-221-8919
Email: kathy.oreilly@philips.com
Twitter: @kathyoreilly
About Royal
Philips:
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. The company is a leader in diagnostic
imaging, image-guided therapy, patient monitoring and health
informatics, as well as in consumer health and home care.
Headquartered in the Netherlands,
Philips' health technology portfolio generated 2015 sales of
EUR 16.8 billion and employs
approximately 69,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
iDevita MA, Bellomo R, Hillman K, et al. Findings of
the first consensus conference on medical emergency teams. Crit
Care Med 2006;34:2463–78